Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Young and Older Folk Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: chowder who wrote (482)	11/24/2021 3:31:51 PM
From: Secret Recipe	Read Replies (1) \| Respond to of 21959

Chowder, where did you get a regular P/E of 25 for COST from? Thanks

To: chowder who wrote (482)	11/24/2021 10:24:16 PM
From: Johnny Canuck	Read Replies (1) \| Respond to of 21959

Curious about the timing of your addtion of NVDA. Obviously a stock growing EPS and sales briskly. Dividend seems to be mid to low single divided over the last 3 and 5 years. NVDA, Stock Quote, Dividend Data, Dates and History - NVIDIA Corp (dividendinvestor.com)

To: chowder who wrote (482)	11/29/2021 4:13:18 PM
From: chowder	2 Recommendations Recommended By Menominee stardusting Read Replies (1) \| Respond to of 21959

Re: Young Folk Portfolio ... Buys and Sells. In the taxable account, today I trimmed an overweight position in PG back to a full position. With the proceeds of this sale I invested equal amounts into AAPL and MSFT. In the Roth Ira, today I sold the position in MKC and trimmed an overweight position in DUK back to a full position. With the proceeds from these sales I invested the entire amount into a new position in TMO. These moves were made with potential capital gain growth as the objective. I'm trying to balance growth & income and right now I'm working on the growth aspect of that equation. BRIEF COMPANY PROFILE: Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. TMO is a highly recommended company at this time. Fidelity has what they call an Equity Summary Score and on a scale of 1-10, the analysts on Fidelity give TMO a rating of 9.0 STRONG BUY. Jefferson Research, which rarely issues a strong buy rating has issued STRONG BUY to TMO. Argus Research gives TMO a BUY rating, their highest rating. TD Ameritrade has a source similar to Fidelity's Equity Summary Score ratings and it's called Smart Score. They give TMO a rating of 9.0 STRONG BUY with 14 of 15 analysts calling it a BUY. The Street gives TMO an A+ BUY rating. CFRA calls TMO a BUY. During the last earnings announcement TMO beat expectations on both earnings and revenue growth. Going forward all 17 analysts reviewing the earnings report have revised their numbers higher going forward. When you take all of this information and connect the dots, it's no wonder that TMO has outperformed the S&P 500 on the 1, 3, 5 and 10 year time frames, an excellent performance record.